Therapy exploits 'addiction' of leukemia cells

April 16, 2012

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

Many cancers are associated with the loss of function of the PTEN , including T-cell (T-ALL). Loss of PTEN leads to unbridled activation of the PI3K/Akt signaling pathway that drives and survival. "We know that there are multiple types of PI3K molecules, designated PI3Kα, β, γ, or δ, the unrestricted activities of which could contribute to these processes," explains senior study author, Dr. Thomas Diacovo, from Columbia University Medical Center. "However, what role, if any, distinct PI3K subtypes play in the pathogenesis of T-ALL was unknown."

Using a mouse model of T-ALL, Dr. Diacovo and colleagues found that in the absence of PTEN, the unrestricted activity of either PI3Kγ or PI3Kδ was sufficient to support and that deletion of both subtypes was required to impair the development of T-ALL. "We found that these two molecules act as a kind of bottleneck in the progression of T-ALL and that the cancer cells can become addicted to these two specific signaling molecules," says Dr. Diacovo. The researchers went on to show that dual inhibition of both PI3K subtypes was necessary to prolong survival of mice with T-ALL and to promote the death of human tumor cells.

"Our work represents a significant advancement in the understanding of the dynamic interplay that exists between PTEN and specific PI3K subtypes in regulating both normal and abnormal T cell development, as well as in sustaining tumor proliferation and survival," concludes Dr. Diacovo. "By pinpointing these therapeutic targets, it may be possible to limit the toxicity that is associated with current T-ALL therapies and to avoid the potential global impact that less selective inhibition of the PI3K/Akt signaling pathway may have on cancer patients."

Explore further: Study identifies potential treatment for lethal childhood leukemia

More information: Subramaniam et al.: "Targeting non-classical oncogenes for therapy in T-ALL." Cancer Cell April 17, 2012/ DOI:10.1016/j.ccr.2012.02.029

Related Stories

Study identifies potential treatment for lethal childhood leukemia

April 16, 2012
Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes — phosphoinositide-3 kinase (PI3K) gamma and delta — play a key role in the development of T-cell acute lymphoblastic ...

New breast cancer model of mutant PI3K recapitulates features of human breast cancer

July 12, 2011
Scientists from the Friedrich Miescher Institute for Biomedical Research have shown that a mutation in the lipid kinase PI3K, which occurs in about 30% of human breast cancers, itself evokes different forms of breast cancer. ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Poliovirus therapy induces immune responses against cancer

September 20, 2017
An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.